According to its website, the U.S. Food and Drug Administration has granted tentative approval for Indian generic pharmaceutical company Strides Acrolan Ltd.’s new fixed-dose combination antiretroviral therapy, Reuters reports (malaysia.news.yahoo.com, 3/26).

According to the article, the drug contains lamivudine, stavudine and nevirapine. Its tentative approval means that while the drug cannot be marketed in the U.S. due to patent laws and other issues, it can be considered for the President’s Emergency Plan for AIDS Relief (PEPFAR), which provides HIV medications to developing countries.